Trial reportEpilepsia2025
Optimizing stimulation parameters for anterior thalamic nuclei deep brain stimulation in epilepsy: A randomized crossover trial.
Trial report in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Gamma suppression correlates with thalamic stimulation therapeutic response in intractable epilepsy.Epilepsia · 2026Article
- A guide to neuromodulation in drug-resistant epilepsy.Epileptic disorders : international epilepsy journal with videotape · 2026Review
- Safety of Intracranial Neuromodulation in Drug-Resistant Pediatric and Adult Epilepsy.Neurology · 2026Article
- Short-Term Modulation of Epileptic Network with Low-Frequency Thalamic Stimulation.medRxiv : the preprint server for health sciences · 2025Article
- Invasive Neurostimulation for the Treatment of Epilepsy.Seminars in neurology · 2025Review
- A comprehensive review of deep brain stimulation for drug-resistant epilepsy.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThe effects of brain stimulation for diseases like epilepsy are delayed, making stimulation optimization difficult. The parameters for anterior thalamic nuclei (ANT) deep brain stimulation (DBS) for focal drug-resistant epilepsy management are often restricted to those used in the SANTE landmark trial. There is little evidence regarding effective alternatives, and low-frequency stimulation is typically neglected. We prospectively compare a widely differing stimulation parameter set to typical settings.
methodsThis randomized, modified crossover, open trial compares the efficacy and safety of an alternative set of parameters using continuous low-frequency stimulation (cLFS) with a longer pulse width (7 Hz, 200 μs, continuous) compared to SANTE's intermittent high-frequency stimulation (iHFS) with a short pulse width (145 Hz, 90 μs, cycling 1 min on/5 min off). After 3 months on a randomly assigned first set, patients are switched to the other settings, unless seizure-free. Patients are re-evaluated after 3 more months, which marks the completion of the trial. After that, they can either remain on the same settings or switch back.
resultsSixteen patients with a median baseline seizure frequency of 13.8 seizures/month (interquartile range [IQR] = 2.7-22.8) were included in the analysis. At trial completion (median follow-up = 30 weeks, IQR = 26-35), ANT-DBS significantly reduced median seizure frequency (62%, IQR = 18-81, Wilcoxon test statistic [W] = 99, p = .008). Both iHFS (33%, IQR = 0-65, W = 81, p = .02) and cLFS (73%, IQR = 30-79, W = 105, p = .001) significantly reduced median seizure frequency. cLFS showed improved median seizure frequency reduction compared to iHFS (W = 63, p = .03) and was not associated with any moderate or severe adverse effects. SIGNIFICANCE: Results support cLFS for ANT-DBS as a safe and effective alternative to typical iHFS parameters. Stimulation with widely differing parameter sets may be as effective as or, in some situations, more effective than typical stimulation parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.